Antibody to cytolethal distending toxin of Campylobacter jejuni
AssigneeCedars-Sinai Medical Center
InventorsMark Pimentel, Christopher Chang
Life of this patent
Estimating the term…
Abstract
Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described.
Claims24
A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof, comprising:
- detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof by using CDT, CdtA, CdtB, CdtC, or a fragment thereof to assay a biological sample obtained from a subject having an IBS symptom.
A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof, comprising:
- detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof by contacting CdtB of Campylobacter jejuni or a fragment thereof with whole blood, plasma or serum obtained from a subject having an IBS symptom, in an assay.
Dependencies are inferred from the claim text.